These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6368760)

  • 81. Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments.
    Tran A; Housset C; Boboc B; Tourani JM; Carnot F; Berthelot P
    J Hepatol; 1991 Jan; 12(1):36-9. PubMed ID: 2007774
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Use of VP-16-213 in the treatment of familial erythrophagocytic lymphohistiocytosis.
    Alvarado CS; Buchanan GR; Kim TH; Zaatari G; Sartain P; Ragab AH
    Cancer; 1986 Mar; 57(6):1097-100. PubMed ID: 3943033
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Epipodophyllin derivative (VP 16-213) in treatment of solid tumours.
    Cavalli F; Sonntag RW; Brunner KW
    Lancet; 1977 Aug; 2(8033):362. PubMed ID: 69974
    [No Abstract]   [Full Text] [Related]  

  • 84. Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors.
    Stewart DJ; Richard MT; Hugenholtz H; Dennery JM; Belanger R; Gerin-Lajoie J; Montpetit V; Nundy D; Prior J; Hopkins HS
    J Neurooncol; 1984; 2(2):133-9. PubMed ID: 6481426
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Clinical pharmacology of intracarotid etoposide.
    Savaraj N; Feun LG; Lu K; Wallace S; Fields WS; Loo TL
    Cancer Chemother Pharmacol; 1986; 16(3):292-4. PubMed ID: 3698170
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Clinical studies with mithramycin.
    Ansfield FJ
    Oncology; 1969; 23(4):283-8. PubMed ID: 5817464
    [No Abstract]   [Full Text] [Related]  

  • 87. Successful treatment of lymphohistiocytic reticulosis with phagocytosis with epipodophyllotoxin VP 16-213.
    Ambruso DR; Hays T; Zwartjes WJ; Tubergen DG; Favara BE
    Cancer; 1980 May; 45(10):2516-20. PubMed ID: 7378987
    [TBL] [Abstract][Full Text] [Related]  

  • 88. High-dose chemotherapy and stem cell transplantation for advanced testicular cancer.
    Voss MH; Feldman DR; Motzer RJ
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):1091-103. PubMed ID: 21806332
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors.
    Voss MH; Feldman DR; Bosl GJ; Motzer RJ
    Hematol Oncol Clin North Am; 2011 Jun; 25(3):557-76, viii -ix. PubMed ID: 21570609
    [TBL] [Abstract][Full Text] [Related]  

  • 90. High-dose etoposide: from phase I to a component of curative therapy.
    Wolff SN; Hainsworth JD; Greco FA
    J Clin Oncol; 2008 Nov; 26(33):5310-2. PubMed ID: 18838698
    [No Abstract]   [Full Text] [Related]  

  • 91. Diagnosis and treatment of patients with testicular germ cell cancer.
    Hartmann JT; Kanz L; Bokemeyer C
    Drugs; 1999 Aug; 58(2):257-81. PubMed ID: 10473019
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy.
    Bokemeyer C; Kuczyk MA; Köhne H; Einsele H; Kynast B; Schmoll HJ
    Ann Hematol; 1996 Jan; 72(1):1-9. PubMed ID: 8605273
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Treatment intensification in disseminated germ-cell tumors.
    Beyer J; Bokemeyer C; Schmoll HJ; Siegert W
    World J Urol; 1994; 12(4):207-13. PubMed ID: 7820143
    [TBL] [Abstract][Full Text] [Related]  

  • 94. VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.
    Einhorn LH
    Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S45-50. PubMed ID: 3815718
    [TBL] [Abstract][Full Text] [Related]  

  • 95. In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy.
    Wolff SN; Grosh WW; Prater K; Hande KR
    Cancer Chemother Pharmacol; 1987; 19(3):246-9. PubMed ID: 3581418
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.
    Henwood JM; Brogden RN
    Drugs; 1990 Mar; 39(3):438-90. PubMed ID: 2184009
    [No Abstract]   [Full Text] [Related]  

  • 97. Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma.
    Harstrick A; Schmoll HJ; Bokemeyer C; Metzner B; Illiger HJ; Berdel W; Ostermann H; Manegold C; Räth U; Siegert W
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S198-202. PubMed ID: 1665492
    [TBL] [Abstract][Full Text] [Related]  

  • 98. High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study.
    Wolff SN; Johnson DH; Hainsworth JD; Greco FA
    J Clin Oncol; 1984 Apr; 2(4):271-4. PubMed ID: 6368760
    [TBL] [Abstract][Full Text] [Related]  

  • 99. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study.
    Wolff SN; Fer MF; McKay CM; Hande KR; Hainsworth JD; Greco FA
    J Clin Oncol; 1983 Nov; 1(11):701-5. PubMed ID: 6366131
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Chemotherapy of refractory germ cell cancer with Etoposide.
    Lederman GS; Garnick MB; Canellos GP; Richie JP
    J Clin Oncol; 1983 Nov; 1(11):706-9. PubMed ID: 6321675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.